专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130209560A1 ABUSE-RESISTANT FORMULATIONS 审中-公开
标题翻译：抗生素制剂
公开(公告)号：US20130209560A1
公开(公告)日：2013-08-15
申请号：US13719908
申请日：2011-02-23
申请人： Ehab Hamed , Carrie Kraling
发明人： Ehab Hamed , Carrie Kraling
IPC分类号： A61K9/00 , A61K31/485
CPC分类号： A61K9/0002 , A61K9/2054 , A61K9/2081 , A61K9/5015 , A61K9/5047 , A61K9/5084 , A61K31/485
摘要： This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance.
摘要翻译：本公开涉及适合于每天两次施用的持续释放口服剂型，其包含含有粘度调节剂的基质和含有氢可酮的包衣颗粒。剂型可以具有释放特征，使得在给药后6小时，小于约80％的氢可酮被释放。此外，剂型可具有醇和/或抗压溃。

2. 发明申请

US20110200681A1 Abuse Resistant Drug Formulation 审中-公开
标题翻译：滥用药物配方
公开(公告)号：US20110200681A1
公开(公告)日：2011-08-18
申请号：US13095434
申请日：2011-04-27
申请人： Walid Habib , Ehab Hamed , Derek Moe , Carrie Kraling , Lisa Hillman
发明人： Walid Habib , Ehab Hamed , Derek Moe , Carrie Kraling , Lisa Hillman
IPC分类号： A61K9/50 , A61K9/52 , A61K31/485 , A61P25/04 , A61P25/36
CPC分类号： A61K9/2095 , A61K9/1652 , A61K9/1694 , A61K9/2081 , A61K9/5047 , A61K31/485
摘要： A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.
摘要翻译：药物组合物可以包括颗粒，其可以包括至少一种易受由与至少两种材料混合的个体滥用的活性药物成分，基本上不溶于水且至少部分醇溶性的第一种物质，醇不溶和至少部分水溶性，其中活性药物成分和两种物质在水和醇存在下造粒。该组合物还可以包括具有抗压溃性的颗粒上的涂层，其可以具有使用醇基溶剂沉积在颗粒上的材料。组合物还包含包含脂肪/蜡的第二颗粒。本发明还包括涂覆的颗粒，组合物的各种剂型，以及生产和压片的方法。

3. 发明授权

US08927025B2 Alcohol-resistant metoprolol-containing extended-release oral dosage forms 有权
标题翻译：耐醇美托洛尔延长释放口服剂型
公开(公告)号：US08927025B2
公开(公告)日：2015-01-06
申请号：US13721128
申请日：2011-05-09
申请人： Ehab Hamed
发明人： Ehab Hamed
IPC分类号： A61K9/16 , A61K9/20 , A61K31/135
CPC分类号： A61K9/16 , A61K9/2022 , A61K9/2027 , A61K9/2054 , A61K31/135
摘要： This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
摘要翻译：本公开涉及包含含有粘度调节剂（但不含脂质）和包含美托洛尔或其药学上可接受的盐或溶剂合物的包衣颗粒的基质的延长释放口服剂型。该剂型具有耐酒精性，并且也具有耐压性。

4. 发明申请

US20130171256A1 ALCOHOL-RESISTANT EXTENDED RELEASE DOSAGE FORMS COMPRISING VENLAFAXINE 审中-公开
标题翻译：耐药性延长的释放剂量，包含维拉费昔芬
公开(公告)号：US20130171256A1
公开(公告)日：2013-07-04
申请号：US13715698
申请日：2011-05-09
申请人： Ehab Hamed
发明人： Ehab Hamed
IPC分类号： A61K9/00 , A61K31/138
CPC分类号： A61K9/0002 , A61K9/205 , A61K9/2054 , A61K9/5047 , A61K31/137 , A61K31/138
摘要： This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
摘要翻译：本公开涉及包含含有粘度调节剂（但不含脂质）的基质和含有文拉法辛或其药学上可接受的盐或溶剂化物的包衣颗粒的延长释放口服剂型。该剂型具有耐酒精性，并且也具有耐压性。

5. 发明申请

US20120225122A1 Abuse-Resistant Formulations 审中-公开
标题翻译：耐药配方
公开(公告)号：US20120225122A1
公开(公告)日：2012-09-06
申请号：US13470963
申请日：2012-05-14
申请人： Ehab HAMED , Manuel A. VEGA ZEPEDA
发明人： Ehab HAMED , Manuel A. VEGA ZEPEDA
IPC分类号： A61K9/26 , A61K9/14 , A61P25/04 , A61K31/485
CPC分类号： A61K9/70 , A61K9/2054 , A61K9/2081 , A61K9/5015 , A61K9/5047 , A61K31/485
摘要： This disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.
摘要翻译：本公开涉及一次一次给药的持续释放口服剂型，其包含含有粘度调节剂的基质和含有氢吗啡酮的包衣颗粒。剂型可以具有释放特征，使得在给药后16小时，少于约85％的氢吗啡酮被释放。此外，剂型可具有醇和/或抗压溃。

6. 发明申请

US20130266660A1 ALCOHOL-RESISTANT METOPROLOL-CONTAINING EXTENDED-RELEASE ORAL DOSAGE FORMS 有权
标题翻译：耐酒精金属醇含量扩大释放口服剂型
公开(公告)号：US20130266660A1
公开(公告)日：2013-10-10
申请号：US13721128
申请日：2011-05-09
申请人： Ehab Hamed
发明人： Ehab Hamed
IPC分类号： A61K9/16
CPC分类号： A61K9/16 , A61K9/2022 , A61K9/2027 , A61K9/2054 , A61K31/135
摘要： This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
摘要翻译：本公开涉及包含含有粘度调节剂（但不含脂质）和包含美托洛尔或其药学上可接受的盐或溶剂合物的包衣颗粒的基质的延长释放口服剂型。该剂型具有耐酒精性，并且也具有耐压性。

7. 发明申请

US20080311205A1 Abuse resistant drug formulation 有权
标题翻译：滥用药物制剂
公开(公告)号：US20080311205A1
公开(公告)日：2008-12-18
申请号：US12075543
申请日：2008-03-12
申请人： Walid A. Habib , Ehab Hamed , Manuel A. Vega Zepeda
发明人： Walid A. Habib , Ehab Hamed , Manuel A. Vega Zepeda
IPC分类号： A61K9/00 , A61K9/14 , A61K31/485
CPC分类号： A61K31/485 , A61K9/14 , A61K9/1652 , A61K9/1694 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/5042 , A61K9/5047 , A61K47/44
摘要： A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.
摘要翻译：药物组合物可以包括可以包括至少一种活性药物成分的涂覆颗粒，特别是易受个体滥用的药物成分。涂覆的颗粒可以包括脂肪/蜡，并且具有改进的控制释放和/或耐压性。还描述了制备这些涂覆的颗粒剂和剂型的方法。

8. 发明申请

US20080069891A1 Abuse resistant drug formulation 审中-公开
标题翻译：滥用药物制剂
公开(公告)号：US20080069891A1
公开(公告)日：2008-03-20
申请号：US11900851
申请日：2007-09-13
申请人： Walid Habib , Ehab Hamed , Derek Moe
发明人： Walid Habib , Ehab Hamed , Derek Moe
IPC分类号： A61K9/16 , A61K47/14 , A61K47/30 , A61P25/04 , A61K47/36 , A61K47/38
CPC分类号： A61K9/2095 , A61K9/1652 , A61K9/1694 , A61K9/2081 , A61K9/5047 , A61K31/485
摘要： A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.
摘要翻译：药物组合物可以包括颗粒，其可以包括至少一种易受由与至少两种材料混合的个体滥用的活性药物成分，基本上不溶于水且至少部分醇溶性的第一种物质，醇不溶和至少部分水溶性，其中活性药物成分和两种物质在水和醇存在下造粒。该组合物还可以包括具有抗压溃性的颗粒上的涂层，其可以具有使用醇基溶剂沉积在颗粒上的材料。组合物还包含包含脂肪/蜡的第二颗粒。本发明还包括涂覆的颗粒，组合物的各种剂型，以及生产和压片的方法。

9. 发明申请

US20080031949A1 High dose orally dissolvable/disintegrable lyophilized dosage form 审中-公开
标题翻译：高剂量口服可溶解/可崩解的冻干剂型
公开(公告)号：US20080031949A1
公开(公告)日：2008-02-07
申请号：US11880531
申请日：2007-07-23
申请人： Ehab Hamed , Rajendra Khankari , Derek Moe , Thanh-Tam Nguyen
发明人： Ehab Hamed , Rajendra Khankari , Derek Moe , Thanh-Tam Nguyen
IPC分类号： A61K9/26 , A61K31/165 , A61K31/425 , A61K31/445
CPC分类号： A61K31/135 , A61K9/0056 , A61K9/1635 , A61K9/1694 , A61K9/19 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2081 , A61K9/2095 , A61K9/5078 , A61K31/165 , A61K31/426 , A61K31/445
摘要： The present invention provides an orally dissolvable/disintegrable, lyophilized dosage form including a protected granulate comprising an active ingredient and a protective granulation binder, which substantially protects the form and/or attributes of a granulate and/or active ingredient, and participates in masking bad tasting active ingredients, such as sulfur-containing materials, and a matrix, and a method for making same. There is also provided a method of treating a patient using any orally dissolvable/disintegrable lyophilized dosage form comprising the steps of placing the dosage form in the mouth of a patient in need of treatment, allowing the dosage form to disintegrate/dissolve sufficiently to allow it, and in particular, the protected granulate, to be swallowed as a solution, suspension or slurry, and swallowing the at least partially disintegrated/dissolved dosage form.
摘要翻译：本发明提供口服可溶解/崩解的冻干剂型，其包括受保护的颗粒，其包含活性成分和保护性造粒粘合剂，其基本上保护颗粒和/或活性成分的形式和/或属性，并参与掩蔽不良品尝活性成分，如含硫材料和基质，以及制备它们的方法。还提供了使用任何口服可溶解/可崩解的冻干剂型治疗患者的方法，包括以下步骤：将剂型放置在需要治疗的患者的口中，允许剂型充分分解/溶解以允许，特别是受保护的颗粒，作为溶液，悬浮液或浆液吞咽，并吞咽至少部分崩解/溶解的剂型。

10. 发明申请

US20130202705A1 ALCOHOL-RESISTANT FORMULATIONS 审中-公开
标题翻译：耐酒精配方
公开(公告)号：US20130202705A1
公开(公告)日：2013-08-08
申请号：US13719952
申请日：2011-05-09
申请人： Ehab Hamed
发明人： Ehab Hamed
IPC分类号： A61K9/00
CPC分类号： A61K9/0002 , A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/5047
摘要： This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance.
摘要翻译：本公开涉及包含含有粘度调节剂（但不含脂质）和包含高水溶性高剂量药物的包衣颗粒的基质的延长释放口服剂型。该剂型具有耐酒精性，并且也具有耐压性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式